Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis
N Ahmad, SD Ahuja, OW Akkerman, JWC Alffenaar… - The Lancet, 2018 - thelancet.com
Background Treatment outcomes for multidrug-resistant tuberculosis remain poor. We aimed
to estimate the association of treatment success and death with the use of individual drugs …
to estimate the association of treatment success and death with the use of individual drugs …
The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis
Global tuberculosis incidence has declined marginally over the past decade, and
tuberculosis remains out of control in several parts of the world including Africa and Asia …
tuberculosis remains out of control in several parts of the world including Africa and Asia …
[HTML][HTML] Global Tuberculosis Report 2020–Reflections on the Global TB burden, treatment and prevention efforts
J Chakaya, M Khan, F Ntoumi, E Aklillu… - International journal of …, 2021 - Elsevier
Abstract The October 2020 Global TB report reviews TB control strategies and United
Nations (UN) targets set in the political declaration at the September 2018 UN General …
Nations (UN) targets set in the political declaration at the September 2018 UN General …
[HTML][HTML] Global health burden of ambient PM2. 5 and the contribution of anthropogenic black carbon and organic aerosols
Chronic exposure to fine particulate matter (PM 2. 5) poses a major global health risk,
commonly assessed by assuming equivalent toxicity for different PM 2. 5 constituents. We …
commonly assessed by assuming equivalent toxicity for different PM 2. 5 constituents. We …
Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies
Tuberculosis remains the world's leading cause of death from an infectious disease,
responsible for an estimated 1 674 000 deaths annually. WHO estimated 600 000 cases of …
responsible for an estimated 1 674 000 deaths annually. WHO estimated 600 000 cases of …
[HTML][HTML] Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised …
RL Goodall, SK Meredith, AJ Nunn, A Bayissa… - The Lancet, 2022 - thelancet.com
Background The STREAM stage 1 trial showed that a 9-month regimen for the treatment of
rifampicin-resistant tuberculosis was non-inferior to the 20-month 2011 WHO-recommended …
rifampicin-resistant tuberculosis was non-inferior to the 20-month 2011 WHO-recommended …
Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis
Background Treatment of multidrug-resistant tuberculosis requires long-term therapy with a
combination of multiple second-line drugs. These drugs are associated with numerous …
combination of multiple second-line drugs. These drugs are associated with numerous …
Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR-and XDR-TB: a multicentre study
SE Borisov, K Dheda, M Enwerem… - European …, 2017 - Eur Respiratory Soc
Large studies on bedaquiline used to treat multidrug-resistant (MDR-) and extensively drug-
resistant tuberculosis (XDR-TB) are lacking. This study aimed to evaluate the safety and …
resistant tuberculosis (XDR-TB) are lacking. This study aimed to evaluate the safety and …
Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study
Background Addition of bedaquiline to treatment for multidrug-resistant tuberculosis was
associated with an increased risk of death in a phase 2b clinical trial, resulting in caution …
associated with an increased risk of death in a phase 2b clinical trial, resulting in caution …
Bedaquiline in the treatment of multidrug-and extensively drug-resistant tuberculosis
Bedaquiline, a diarylquinoline, improved cure rates when added to a multidrug-resistant
tuberculosis (MDR-TB) treatment regimen in a previous placebo-controlled, phase 2 trial …
tuberculosis (MDR-TB) treatment regimen in a previous placebo-controlled, phase 2 trial …